Security key
23255M204
Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN)
CUSIP: 23255M204
Q1 2024 13F Holders as of 31 Mar 2024
- Type / Class
- Equity / Common Stock, no par value
- Shares outstanding
- 3,367,000
- Total 13F shares
- 1,070,254
- Share change
- +764
- Total reported value
- $3,424,719
- Price per share
- $3.20
- Number of holders
- 15
- Value change
- +$2,411
- Number of buys
- 5
- Number of sells
- 3
Report period
Q1 2024
Institutions
15
Top holders
10
CYCN full security history
Newer quarter: Q2 2024
Previous quarter: Q4 2023
Cyclerion Therapeutics, Inc. SEC filings
Cyclerion Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 23255M204
Recent filing periods:
Top shareholders of CYCN - Cyclerion Therapeutics, Inc. - Common Stock, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Slate Path Capital LP |
13F
|
Company |
11%
|
357,880
|
$1,198,898 | — | 31 Dec 2023 | |
| MFN Partners Management, LP |
13F
|
Company |
5%
|
169,460
|
$567,691 | — | 31 Dec 2023 | |
| TYNDALL CAPITAL PARTNERS L P |
13F
|
Company |
4.9%
|
164,429
|
$550,837 | — | 31 Dec 2023 | |
| FMR LLC |
13F
|
Company |
4.8%
|
162,849
|
$545,545 | — | 31 Dec 2023 | |
| Artal Group S.A. |
13F
|
Company |
4.1%
|
138,955
|
$466,000 | — | 31 Dec 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.93%
|
31,259
|
$104,748 | — | 31 Dec 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.7%
|
23,490
|
$78,692 | — | 31 Dec 2023 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.51%
|
17,169
|
$57,516 | — | 31 Dec 2023 | |
| UBS Group AG |
13F
|
Company |
0.07%
|
2,228
|
$7,464 | — | 31 Dec 2023 | |
| MORGAN STANLEY |
13F
|
Company |
0.02%
|
698
|
$2,338 | — | 31 Dec 2023 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.02%
|
540
|
$1,809 | — | 31 Dec 2023 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.01%
|
330
|
$1,000 | — | 31 Dec 2023 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.01%
|
187
|
$626 | — | 31 Dec 2023 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
15
|
$50 | — | 31 Dec 2023 | |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO |
13F
|
Company |
0%
|
1
|
$3 | — | 31 Dec 2023 | |
| Terrance McGuire |
3/4/5
|
Director |
—
class O/S missing
|
42,010
|
$142,624 | — | 30 Nov 2023 | |
| Errol B. Desouza |
3/4/5
|
Director |
—
class O/S missing
|
30,000
|
$101,850 | — | 30 Nov 2023 | |
| Dina Katabi |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
$67,900 | — | 30 Nov 2023 | |
| Steven Hyman |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
$67,900 | — | 30 Nov 2023 | |
| Andreas Busch |
3/4/5
|
Chief Scientific Officer |
—
class O/S missing
|
135,000
|
— | — | 20 Jan 2022 | |
| Anjeza Gjino |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
135,000
|
— | — | 20 Jan 2022 | |
| Cheryl Gault |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
135,000
|
— | — | 20 Jan 2022 | |
| George H. Conrades |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 14 Jun 2022 | |
| Marsha Fanucci |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 14 Jun 2022 | |
| Michael Mendelsohn |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 14 Jun 2022 | |
| Ole Isacson |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 14 Jun 2022 | |
| Stephanie Lovell |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 14 Jun 2022 | |
| Kevin Churchwell |
3/4/5
|
Director |
—
class O/S missing
|
10,000
|
— | — | 24 Jun 2021 |
Institutional Holders of Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) as of Q1 2024
As of 31 Mar 2024,
Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) was held by
15 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,070,254 shares.
The largest 10 holders included
Slate Path Capital LP, MFN Partners Management, LP, TYNDALL CAPITAL PARTNERS L P, FMR LLC, Artal Group S.A., GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, BlackRock Inc., UBS Group AG, and MORGAN STANLEY.
This page lists
15
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2024 vs Q4 2023 Across Filers
Q4 2023 holders
15
Q1 2024 holders
15
Holder diff
0
| Investor | Q4 2023 Shares | Q1 2024 Shares | Share Diff | Share Chg % | Q4 2023 Value $ | Q1 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.